On Wednesday, Evercore ISI adjusted its price target on agilon health Inc (NYSE:AGL), increasing it to $5.50 from the previous target of $5.00. The firm maintained an In Line rating for the company's shares. The adjustment follows agilon health's recent financial report and management's discussion of various operational aspects.
The firm highlighted several key points from agilon health's latest financial disclosure. Management's discussion focused on the impact of exiting certain payor contracts and the progression of these changes. Additionally, they noted favorable developments in rate negotiations, including retroactive financial relief for fiscal year 2023 in some instances.
Furthermore, the analyst pointed out the positive implications of the early implementation of the Class of 2025, which is expected to enhance cohort performance, particularly in existing markets. The report also acknowledged agilon health's progress in achieving more favorable economic terms.
Despite these positive developments, Evercore ISI expressed caution regarding the medical loss ratio (MLR), citing persistent trends of high utilization. The firm's revised fiscal year 2024 estimates reflect an improved EBITDA projection based on stronger medical margins reported in the recent quarter.
However, concerns about the long-term funding environment and its potential impact on growth were noted. These concerns have led Evercore ISI to maintain a cautious stance, with the new price target of $5.50 representing approximately 15.4 times the projected fiscal year 2026 EBITDA.
InvestingPro Insights
According to the latest data from InvestingPro, agilon health Inc (NYSE:AGL) is navigating a challenging financial landscape. With a market capitalization of $2.05 billion, the company's aggressive share buyback strategy is noteworthy. This is underscored by the fact that AGL holds more cash than debt on its balance sheet, which may provide a degree of financial flexibility. Furthermore, the company's revenue has grown significantly, with an 80.74% increase in the last twelve months as of Q4 2023. Despite this revenue growth, AGL's gross profit margin remains low at 1.61%, reflecting the concerns about profitability that analysts have expressed.
InvestingPro Tips highlight that AGL's stock has suffered a considerable decline over the past year, with a 1-year price total return of -80.75%. Additionally, the company is trading at a low revenue valuation multiple, indicating that the market may be undervaluing AGL's sales. The InvestingPro product provides additional insights into AGL's financial health and future prospects, with 9 more tips available to guide potential investors. For those interested in a deeper analysis, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.